BridgeBio Pharma, Inc. (BBIO): Price and Financial Metrics


BridgeBio Pharma, Inc. (BBIO)

Today's Latest Price: $49.13 USD

0.66 (1.36%)

Updated Nov 27 1:00pm

Add BBIO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

BBIO Stock Summary

  • BBIO's went public 1.42 years ago, making it older than merely 1.88% of listed US stocks we're tracking.
  • With a price/sales ratio of 274.39, BridgeBio Pharma Inc has a higher such ratio than 98.4% of stocks in our set.
  • With a year-over-year growth in debt of 544.85%, BridgeBio Pharma Inc's debt growth rate surpasses 96.57% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to BridgeBio Pharma Inc, a group of peers worth examining would be FOLD, ARDX, QURE, DCPH, and ALBO.
  • Visit BBIO's SEC page to see the company's official filings. To visit the company's web site, go to bridgebio.com.

BBIO Stock Price Chart Interactive Chart >

Price chart for BBIO

BBIO Price/Volume Stats

Current price $49.13 52-week high $50.09
Prev. close $48.47 52-week low $14.23
Day low $48.24 Volume 242,400
Day high $50.09 Avg. volume 730,479
50-day MA $40.64 Dividend yield N/A
200-day MA $32.56 Market Cap 6.02B

BridgeBio Pharma, Inc. (BBIO) Company Bio


BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.


BBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

BBIO Latest Social Stream


Loading social stream, please wait...

View Full BBIO Social Stream

Latest BBIO News From Around the Web

Below are the latest news stories about BridgeBio Pharma Inc that investors may wish to consider to help them evaluate BBIO as an investment opportunity.

FDA accepts BridgeBio application for BBP-870 for ultra-rare metabolic disorder

The FDA accepts for review BridgeBio Pharma's (BBIO) marketing application seeking approval of BBP-870 (ORGN001 at subsidiary Origin Biosciences) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare inborn error of metabolism characterized by irreversible brain damage in newborns.Fosdenopterin is a cyclic pyranopterin monophosphate (cPMP)...

Seeking Alpha | September 29, 2020

BridgeBio Pharma (BBIO) R&D Day Presentation - Slideshow

The following slide deck was published by BridgeBio Pharma, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 29, 2020

Perceptive Advisors Launches LianBio with Multiple Strategic Alliances and Establishes Operating Platform

SHANGHAI & PRINCETON, N.J.--(BUSINESS WIRE)---- $BBIO #BridgeBio--Perceptive Advisors launches LianBio with multiple strategic alliances to develop and commercialize therapeutics in China and major Asian markets.

Business Wire | August 11, 2020

BridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia

SAN FRANCISCO, July 15, 2020 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that the first child with achondroplasia has been dosed with.

Yahoo | July 15, 2020

BridgeBio Pharma’s Phoenix Tissue Repair to Highlight Interim Phase 1/2 Study Data in a Presentation at the Society for Pediatric Dermatology’s 45th Annual Meeting

BOSTON, July 10, 2020 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Phoenix Tissue Repair (PTR) today announced an upcoming presentation of interim data from an ongoing.

Yahoo | July 10, 2020

Read More 'BBIO' Stories Here

BBIO Price Returns

1-mo 28.01%
3-mo 64.53%
6-mo 69.41%
1-year 69.41%
3-year N/A
5-year N/A
YTD 40.17%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7049 seconds.